Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07623668 · ClinicalTrials.gov registry record · Phase 3

Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

A Phase 3 study, sponsored by Oculis.

Recruiting
Registry status
Phase 3
Development phase
210
Enrollment target

NCT07623668: Recruiting Phase 3 study, sponsored by Oculis.

NCT07623668 is a Phase 3 study that is actively recruiting participants, run by Oculis. The registered enrollment target is 210 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07623668, a Phase 3 study, is actively recruiting participants, sponsored by Oculis.

RECRUITING
Registry status
Phase 3
Development phase
210 participants
Enrollment target

Study Summary

The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).

Interventions

  • OTHER Placebo
  • DRUG Methylprednisolone
  • DRUG Privosegtor

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2026-05-28
Est. Completion 2028-12
Phase Phase 3
Oculis

8 total trials

What NCT07623668 shows while recruiting

NCT07623668 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT07623668 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07623668 about?

NCT07623668 is a clinical study titled "Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research". The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolon...

What is the current status of trial NCT07623668?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2026-05-28. Estimated completion is 2028-12.

What interventions are being tested in trial NCT07623668?

The interventions under investigation include: Placebo (OTHER), Methylprednisolone (DRUG), Privosegtor (DRUG).

Who is sponsoring clinical trial NCT07623668?

This trial is sponsored by Oculis, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07623668's enrollment target sits among peer trials

210 1338th of 2000 higher than 656 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

  • NCT03544489 · 210 participants · Phase 2

    Effectiveness of Exercise After an ICD

  • NCT04408430 · 210 participants · NA

    The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07623668, the US trial registry maintained by the National Library of Medicine. NCT07623668 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.